RecruitingPhase 2NCT04872543
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Studying Malignant peripheral nerve sheath tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Ping Chi, MD, PhD, M.DMemorial Sloan Kettering Cancer Center
- Intervention
- ASTX727(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2021 – 2027
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Collaborators
Taiho Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04872543 on ClinicalTrials.govOther trials for Malignant peripheral nerve sheath tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06693284A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]University of Minnesota
- RECRUITINGPHASE1NCT04222413Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT03872427Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyNational Cancer Institute (NCI)
- RECRUITINGNANCT03141021Multi-Institutional Registry for Malignant Peripheral Nerve Sheath TumorsWashington University School of Medicine
See all trials for Malignant peripheral nerve sheath tumor →